Prognostic impact of MYC/BCL2 coexpression in DLBCL risk-stratified according to clinicopathologic parameters. (A-B) OS (A) and PFS (B) of patients with MYC⁺BCL2⁺ DLBCL of the GCB subtype in the training set. (C-D) OS (C) and PFS (D) of patients with MYC⁺BCL2⁺ DLBCL of the ABC subtype in the training set. (E-F) OS (E) and PFS (F) of patients with MYC⁺BCL2⁺ DLBCL risk-stratified according to IPI risk scores in the training set. DP, MYC/BCL2 double-positive; Non-DP, non–double positive.